ImmuPharma PLC (AIM:IMM) has raised £2.91 million in an oversubscribed equity offering, backed by key investors like Lanstead. CEO Tim McCarthy says the funds will push forward its P140 autoimmune platform, boosting talks with potential pharma partners.
hVIVO PLC (AIM:HVO) has signed a £2 million contract with a biotech client to advance its human metapneumovirus (hMPV) study. CEO Yamin ‘Mo’ Khan says the study could accelerate vaccine development for the virus, which is increasingly affecting children.
Ananda Pharma Plc (AQSE:ANA) has completed the final technical batch of MRX1, moving closer to clinical trials for treating CIPN and endometriosis pain. Finance director Jeremy Sturgess-Smith says trials in Edinburgh and Australia are next, with hopes for regulatory approvals.
Ondo InsurTech PLC (LSE:ONDO) is expanding its LeakBot technology in the US, now working with Privilege Underwriters Reciprocal Exchange (PURE) in six new states. CEO Craig Foster says Ondo is following a state-by-state approach to grow its insurer partnerships.
SEEEN plc (AIM:SEEN) has reported strong growth, with revenue jumping from $2.1 million in 2023 to $3.2 million in 2024. CEO Adrian Hargrave says the company’s AI-driven video platform is gaining traction in sports, e-commerce, and education, helping creators monetise content.
